匹多莫德对反复呼吸道感染患儿免疫功能及临床疗效的影响

目的 探讨匹多莫得辅助治疗小儿呼吸道反复感染的临床疗效及其对患儿免疫功能的影响。方法 选择广元市妇幼保健院2013年8月—2016年1月收治的呼吸道反复感染患儿150例，随机分为2组，每组75例，对照组患儿接受常规抗生素治疗，治疗组患儿在对照组治疗基础上加用匹多莫得治疗，持续治疗2个月，治疗结束后随访4个月，比较两组患儿治疗期间临床症状以及机体免疫功能的变化，同时比较随访期间两组患儿的临床疗效。结果 治疗后，治疗组患儿咳嗽、发热、扁桃体发炎以及肺部哮鸣音消失的时间显著短于对照组（P＜0.05）。治疗后，两组患儿血清免疫球蛋白水平较治疗前有所升高（P＜0.05），其中治疗组患儿升高更为明显，与对照组比较具有统计学意义（P＜0.05）；治疗后两组患儿T细胞亚群CD3⁺、CD4⁺、CD8⁺以及NK细胞相对活性都明显升高（P＜0.05），且CD4+/CD8+相对含量同样升高（P＜0.05），同时比较两组患儿治疗后各细胞水平，统计结果表明治疗组患儿改善情况更为明显（P＜0.05）。治疗后，治疗组患儿治疗总有效率显著高于对照组（P＜0.05），且治疗组患儿随访期间感染复发的次数显著少于对照组（P＜0.05），且复发持续时间明显较短（P＜0.05）。结论 匹多莫得联合抗菌药物治疗小儿呼吸道反复感染效果显著，有效改善机体免疫功能，减少感染复发次数，值得临床推广应用。

Effect of pidotimod on immunologic functions and clinical curative efficacy for patients undergoing recurrent respiratory tract infections

Objective To evaluate the effect of pidotimod combined with antibacterials on the immunologic functions and clinical curative efficacy for patients undergoing recurrent respiratory tract infections. Methods Patients with recurrent respiratory tract infections (150 cases) were enrolled in Maternal and Child Health Hospital of Guangyuan from August 2013 to January 2016, which divided to two groups randomly, Group A (n = 75) accepted traditional antibacterials treatment, and Group B (n = 75) adopted pidotimod combined with antibacterials. The clinical symptom and immunologic functions of patients during treatment were tested, and the clinical curative efficacy of patients was evaluated in the follow-up period. Results After treatment, the disappear time of cough, fever, tonsil inflammation and pulmonary wheezing in treatment group was significantly shorter than that of control group (P< 0.05). After treatment, the levels of serum immunoglobulin in two groups were higher than those before treatment (P< 0.05), and the treatment group was significantly higher than control group (P< 0.05). After treatment, the relative activities of CD3⁺, CD4⁺, CD8⁺, and NK cells in two groups increased significantly (P< 0.05), the relative content of CD4⁺/CD8⁺ was also increased (P< 0.05), and the improvement of above indexes in the treatment group was more obvious than those in control group (P< 0.05). After treatment, total effective rate of treatment group was significantly higher than that of control group (P< 0.05), the recurrence of infection in the treatment group is significantly lower than that in the control group (P< 0.05), and the recurrence duration was significantly shorter than control group (P< 0.05). Conclusion The clinical curative of pidotimod combined with antibacterials was remarkable for patients of recurrent respiratory tract infections, which deserved popularization not only improving the immunologic functions, but also decreasing the times of recurrence.